Bluejay Diagnostics Stock Today

BJDX Stock  USD 4.22  0.52  14.05%   

Performance

Modest

 
Weak
 
Strong

Odds Of Distress

High

 
High
 
Low
Bluejay Diagnostics is trading at 4.22 as of the 26th of February 2025; that is 14.05 percent increase since the beginning of the trading day. The stock's open price was 3.7. Bluejay Diagnostics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain
Health Care Equipment & Services
IPO Date
10th of November 2021
Category
Healthcare
Classification
Health Care
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts. The company has 552.85 K outstanding shares of which 14.4 K shares are currently shorted by private and institutional investors with about 0.09 trading days to cover. More on Bluejay Diagnostics

Bluejay Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors)
Debt Levels
Bluejay Diagnostics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bluejay Diagnostics' financial leverage. It provides some insight into what part of Bluejay Diagnostics' total assets is financed by creditors.
Liquidity
Bluejay Diagnostics currently holds 352.98 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Bluejay Diagnostics has a current ratio of 17.06, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Bluejay Diagnostics' use of debt, we should always consider it together with its cash and equity.

Depreciation

943,003
Bluejay Diagnostics (BJDX) is traded on NASDAQ Exchange in USA. It is located in 360 Massachusetts Avenue, Acton, MA, United States, 01720 and employs 10 people. Bluejay Diagnostics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.33 M. Bluejay Diagnostics conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 552.85 K outstanding shares of which 14.4 K shares are currently shorted by private and institutional investors with about 0.09 trading days to cover. Bluejay Diagnostics currently holds about 15.34 M in cash with (8.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76.
Check Bluejay Diagnostics Probability Of Bankruptcy
Ownership Allocation
Almost 92.61 percent of Bluejay Diagnostics outstanding shares are held by general public with 0.69 (percent) owned by insiders and only 6.7 % by other corporate entities.
Check Bluejay Ownership Details

Bluejay Stock Institutional Holders

InstituionRecorded OnShares
Two Sigma Investments Llc2024-12-31
0.0
Virtu Financial Llc2024-09-30
0.0
Two Sigma Securities, Llc2024-12-31
0.0
Hrt Financial Llc2024-12-31
0.0
Sabby Management Llc2024-09-30
305.2 K
Citadel Advisors Llc2024-09-30
52.2 K
Ubs Group Ag2024-12-31
1.9 K
Tower Research Capital Llc2024-12-31
554
Bank Of America Corp2024-12-31
4.0
Advisor Group Holdings, Inc.2024-09-30
3.0
Warberg Asset Management Llc2024-09-30
0.0
View Bluejay Diagnostics Diagnostics

Bluejay Diagnostics Historical Income Statement

At this time, Bluejay Diagnostics' Net Interest Income is fairly stable compared to the past year. Depreciation And Amortization is likely to rise to about 943 K in 2025, whereas Interest Expense is likely to drop slightly above 22.8 K in 2025. View More Fundamentals

Bluejay Stock Against Markets

Bluejay Diagnostics Corporate Management

Kenneth CPAChief OfficerProfile
Kevin VanceChief OfficerProfile
Jason CookChief OfficerProfile
Mark MDChief AdvisorProfile
Les DeLucaVice OperationsProfile
Eryn GrahamMarketing ManagerProfile

Additional Tools for Bluejay Stock Analysis

When running Bluejay Diagnostics' price analysis, check to measure Bluejay Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluejay Diagnostics is operating at the current time. Most of Bluejay Diagnostics' value examination focuses on studying past and present price action to predict the probability of Bluejay Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluejay Diagnostics' price. Additionally, you may evaluate how the addition of Bluejay Diagnostics to your portfolios can decrease your overall portfolio volatility.